DK0710121T3 - Fremgangsmåde til behandling af dissemineret sklerose - Google Patents

Fremgangsmåde til behandling af dissemineret sklerose

Info

Publication number
DK0710121T3
DK0710121T3 DK93917954T DK93917954T DK0710121T3 DK 0710121 T3 DK0710121 T3 DK 0710121T3 DK 93917954 T DK93917954 T DK 93917954T DK 93917954 T DK93917954 T DK 93917954T DK 0710121 T3 DK0710121 T3 DK 0710121T3
Authority
DK
Denmark
Prior art keywords
necrosis factor
tumour necrosis
disseminated sclerosis
treating disseminated
factor receptor
Prior art date
Application number
DK93917954T
Other languages
Danish (da)
English (en)
Inventor
John Leslie Turk
David Baker
Marc Feldmann
Original Assignee
Kennedy Inst Of Rheumatology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kennedy Inst Of Rheumatology filed Critical Kennedy Inst Of Rheumatology
Application granted granted Critical
Publication of DK0710121T3 publication Critical patent/DK0710121T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preliminary Treatment Of Fibers (AREA)
  • Treatment Of Fiber Materials (AREA)
  • Spinning Or Twisting Of Yarns (AREA)
  • Transplanting Machines (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK93917954T 1993-07-30 1993-07-30 Fremgangsmåde til behandling af dissemineret sklerose DK0710121T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB1993/001614 WO1995003827A1 (fr) 1993-07-30 1993-07-30 Procede de traitement de la sclerose en plaques

Publications (1)

Publication Number Publication Date
DK0710121T3 true DK0710121T3 (da) 2001-02-05

Family

ID=10729416

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93917954T DK0710121T3 (da) 1993-07-30 1993-07-30 Fremgangsmåde til behandling af dissemineret sklerose

Country Status (11)

Country Link
US (1) US5958409A (fr)
EP (2) EP0710121B1 (fr)
JP (1) JPH09509646A (fr)
AT (1) ATE196849T1 (fr)
AU (1) AU4719093A (fr)
DE (1) DE69329558T2 (fr)
DK (1) DK0710121T3 (fr)
ES (1) ES2153384T3 (fr)
GR (1) GR3035196T3 (fr)
PT (1) PT710121E (fr)
WO (1) WO1995003827A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US7070783B1 (en) * 1995-05-09 2006-07-04 The Mathilda And Terence Kennedy Institute Of Rheumatology Small molecular weight TNF receptor multimeric molecule
DK0839046T3 (da) * 1995-07-14 2002-02-18 Applied Research Systems TNF-receptor og steroidhormon i en kombinationsterapi
US7012060B1 (en) 1995-07-14 2006-03-14 Applied Research Systems Ars Holding N.V. TNF receptor and steroid hormone in a combined therapy
US7608262B2 (en) 1996-02-16 2009-10-27 The Kennedy Institute Of Rheumatology Methods of preventing or treating thrombosis with tumor necrosis factor antagonists
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
IL127851A0 (en) * 1998-12-30 1999-10-28 Applied Research Systems Inhibition of TNF activity
US8119127B2 (en) * 1999-02-24 2012-02-21 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
US6982089B2 (en) 1999-02-24 2006-01-03 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
USRE45976E1 (en) * 1999-02-24 2016-04-19 Tact Ip, Llc Methods of inhibiting the action of TNF for neurological conditions by administering etanercept intrathecally
AU6929100A (en) * 1999-08-23 2001-03-19 Biocrystal Limited Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis
CA2975521A1 (fr) * 2001-05-30 2002-12-05 Genentech, Inc. Anticorps anti-ngf pour le traitement de divers troubles
US20050175585A1 (en) * 2001-06-11 2005-08-11 Transition Therapeutics Inc. Combination therapies using vitamin B12 and interferon for treatment of viral proliferative and inflammatory disesases
JP2004536819A (ja) * 2001-06-11 2004-12-09 トランジション・セラピューティックス・インコーポレーテッド ウイルス性、増殖性および炎症性の疾患の治療のためにビタミンｂ１２および治療薬を用いた複合治療
PL209734B1 (pl) * 2002-02-20 2011-10-31 Emisphere Tech Inc Preparat farmaceutyczny zawierający związek GLP-1 i czynnik dostarczający oraz jego zastosowanie
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
US7285269B2 (en) 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
US7101978B2 (en) 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
US7435799B2 (en) 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
US8236306B2 (en) * 2004-12-18 2012-08-07 Edward Lewis Tobinick Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers
EP1987066B1 (fr) * 2006-02-22 2010-12-29 University of Zürich Procédés de traitement des maladies démyélinisantes
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
KR102085557B1 (ko) 2013-03-14 2020-03-06 엘커메스 파마 아일랜드 리미티드 푸마레이트의 프로드럭 및 다양한 질환을 치료하는데 있어서의 이들의 용도
JP6337135B2 (ja) 2014-02-24 2018-06-06 アルカーメス ファーマ アイルランド リミテッド フマル酸エステルのスルホンアミドプロドラッグ及びスルフィンアミドプロドラッグ並びに種々の疾患の治療におけるその使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL98078A0 (en) * 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
JP3443119B2 (ja) * 1989-08-07 2003-09-02 ペプテック リミテッド 腫瘍壊死因子結合リガンド
EP0939121B2 (fr) * 1989-09-12 2007-12-26 AHP Manufacturing B.V. Protéines liant le TNF
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
DE4202665A1 (de) * 1992-01-28 1993-07-29 Schering Ag Prostacyclin- und carbacyclinderivate als mittel zur behandlung von multipler sklerose

Also Published As

Publication number Publication date
US5958409A (en) 1999-09-28
DE69329558T2 (de) 2001-05-31
EP0710121A1 (fr) 1996-05-08
ES2153384T3 (es) 2001-03-01
GR3035196T3 (en) 2001-04-30
JPH09509646A (ja) 1997-09-30
WO1995003827A1 (fr) 1995-02-09
AU4719093A (en) 1995-02-28
EP0710121B1 (fr) 2000-10-11
DE69329558D1 (de) 2000-11-16
EP1004312A1 (fr) 2000-05-31
PT710121E (pt) 2001-04-30
ATE196849T1 (de) 2000-10-15

Similar Documents

Publication Publication Date Title
DK0710121T3 (da) Fremgangsmåde til behandling af dissemineret sklerose
FI943805A0 (fi) Substituoituja adeniinijohdannaisten käyttö multippeliskleroosin hoitoon
BG43866A3 (en) Method for preparing of derivatives of 2, 2'- imino- bis- ethanol
DK0603305T3 (da) Anvendelse af et thymosin til behandling af hepatitis C
IT1261949B (it) Composizione terapeutica a base di interferone umano, impiego di interferone umano in tale composizione e relativo metodo.
NO941780D0 (no) Fremgangsmåte for behandling av TNF-avhengig inflammasjon under anvendelse av tumornekrosefaktorantagonister
NO912794D0 (no) Boresystem og fremgangsmaate for styring av retningen paa boringer i grunnformasjoner.
IT8424009A0 (it) Composizioni analgesiche ed anti-infiammatorie migliorate, comprendente xantine e metodi di utilizzare le stesse.
NO850058L (no) Modifisert kolofoniumharpiks, og fremgangsmaate til fremstilling og anvendelse derav
IT8622630A0 (it) Anticorpi monoclonali crossreattivi e cross-protettivi contro sierotipi di p. aeruginosa.
DK149990A (da) Familie af modificerede antistoffer med hoej affinitet til cancerbehandling
DK183590D0 (da) Fremgangsmaade til reduktion af immunoglobulin e-responser
IT8967343A0 (it) Anticorpo umano monoclonale ed ibridoma che produce il medesimo
NO910473D0 (no) Fremgangsmaate for fremstilling av tricykliske aminer.
ATE155345T1 (de) Gegengift immunsera
NO853342L (no) Fremgangsmaate og anordning for framstilling av hulplater og andre byggeelementer, saerlig av betong.
DK81691D0 (da) Fremgangsmaade til forhindring eller reduktion af eosinofili
FI915127L (fi) Mineraloljemellandestillat med foerbaettrade flytegenskaper i koeld.
DE59207900D1 (de) Iloprost mit wirkung gegen cerebrale malaria
DK328088A (da) Farmaceutisk komposition til behandling af tumorer
DK0588873T3 (da) Behandling af levercancer
FR2700162B1 (fr) Composite liant hydraulique-granulat lignocellulosique, sa fabrication et ses applications.
DE69102719D1 (de) Halbleiterbauelement mit MOS Transitor und dessen Herstellungsverfahren.
FI915244A7 (fi) Biometallurginen prosessi, jossa suoritetaan mineraaliyhdisteiden biohapetus
DE58901521D1 (de) Tragschichtfertiger.